UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 11, 2017
Dextera Surgical Inc.
(Exact Name of Registrant as Specified in its Charter)
| | | | |
Delaware (State or Other Jurisdiction of Incorporation) | | 000-51772 (Commission File Number) | | 94-3287832 (IRS Employer Identification No.) |
| | |
900 Saginaw Drive, Redwood City, CA (Address of Principal Executive Offices) | | 94063 (Zip Code) |
Registrant’s telephone number, including area code: (650) 364-9975
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01. Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing.
On December 11, 2017, Dextera Surgical, Inc. received from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) a letter notifying Dextera that the Nasdaq Hearings Panel has determined to delist Dextera’s common stock from Nasdaq, and that trading in Dextera’s common stock will be suspended effective at the open of business on December 13, 2017. Dextera had appealed the Staff’s previous delisting notices for failure to comply with the minimum bid price requirement in Nasdaq listing rule 5550(a)(2), and minimum stockholders’ equity requirement in Nasdaq listing rule 5550(b)(1), to the Nasdaq Hearings Panel, which appeal was heard by the Nasdaq Hearings Panel on December 7, 2017.
Dextera has applied to the OTC Markets Group for a listing of its common stock on the OTCQB Venture Market.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
| | Dextera Surgical Inc. | |
| | | | |
| | | |
Date: December 11, 2017 | | /s/ Robert Y. Newell | |
| | Robert Y. Newell | |
| | Chief Financial Officer | |
